| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 235 | 2024 | 5128 | 18.320 |
Why?
|
| Antipsychotic Agents | 134 | 2024 | 3077 | 9.490 |
Why?
|
| Depressive Disorder, Major | 83 | 2024 | 4809 | 9.250 |
Why?
|
| Antidepressive Agents | 74 | 2024 | 2901 | 7.270 |
Why?
|
| Lithium | 50 | 2024 | 599 | 6.910 |
Why?
|
| Antimanic Agents | 46 | 2024 | 523 | 6.890 |
Why?
|
| Suicide, Attempted | 51 | 2024 | 1413 | 6.110 |
Why?
|
| Suicide | 44 | 2023 | 1606 | 5.540 |
Why?
|
| Mood Disorders | 25 | 2023 | 1127 | 4.620 |
Why?
|
| Psychotic Disorders | 66 | 2023 | 3274 | 3.950 |
Why?
|
| Lithium Compounds | 21 | 2024 | 226 | 3.750 |
Why?
|
| Suicidal Ideation | 26 | 2023 | 1466 | 3.590 |
Why?
|
| Psychotropic Drugs | 32 | 2023 | 880 | 3.260 |
Why?
|
| Schizophrenia | 75 | 2023 | 6975 | 3.140 |
Why?
|
| Clozapine | 30 | 2023 | 509 | 3.120 |
Why?
|
| Anticonvulsants | 37 | 2024 | 1920 | 2.960 |
Why?
|
| Temperament | 10 | 2023 | 300 | 2.950 |
Why?
|
| Depressive Disorder | 59 | 2021 | 3712 | 2.930 |
Why?
|
| Receptors, Dopamine D2 | 40 | 2008 | 471 | 2.810 |
Why?
|
| Receptors, Dopamine | 62 | 2013 | 291 | 2.810 |
Why?
|
| Antidepressive Agents, Tricyclic | 21 | 2020 | 427 | 2.680 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 36 | 2023 | 1988 | 2.010 |
Why?
|
| Mental Disorders | 49 | 2022 | 6871 | 1.960 |
Why?
|
| Lithium Carbonate | 15 | 2010 | 179 | 1.910 |
Why?
|
| Serotonin | 40 | 2017 | 1045 | 1.900 |
Why?
|
| Benzodiazepines | 20 | 2021 | 1136 | 1.810 |
Why?
|
| Psychopharmacology | 4 | 2022 | 146 | 1.720 |
Why?
|
| Valproic Acid | 13 | 2021 | 444 | 1.680 |
Why?
|
| Pirenzepine | 9 | 2003 | 116 | 1.610 |
Why?
|
| Depression | 24 | 2023 | 8230 | 1.590 |
Why?
|
| Corpus Striatum | 54 | 2008 | 1218 | 1.550 |
Why?
|
| Apomorphine | 56 | 2007 | 148 | 1.520 |
Why?
|
| Dopamine | 70 | 2003 | 1582 | 1.520 |
Why?
|
| Italy | 23 | 2021 | 851 | 1.480 |
Why?
|
| Humans | 540 | 2024 | 766117 | 1.420 |
Why?
|
| Controlled Clinical Trials as Topic | 5 | 2015 | 187 | 1.420 |
Why?
|
| Prosencephalon | 18 | 2008 | 305 | 1.410 |
Why?
|
| Finasteride | 2 | 2021 | 86 | 1.410 |
Why?
|
| Psychiatric Status Rating Scales | 50 | 2023 | 6020 | 1.400 |
Why?
|
| Risperidone | 13 | 2022 | 383 | 1.370 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2021 | 112 | 1.360 |
Why?
|
| Hospitals, Psychiatric | 14 | 2019 | 318 | 1.360 |
Why?
|
| Receptors, Dopamine D1 | 27 | 2008 | 276 | 1.320 |
Why?
|
| Anxiety Disorders | 17 | 2022 | 2741 | 1.280 |
Why?
|
| Randomized Controlled Trials as Topic | 33 | 2022 | 10380 | 1.260 |
Why?
|
| Membrane Transport Proteins | 17 | 2005 | 1029 | 1.250 |
Why?
|
| Aporphines | 25 | 2008 | 32 | 1.240 |
Why?
|
| Dopamine Antagonists | 27 | 2007 | 279 | 1.240 |
Why?
|
| Psychiatry | 16 | 2014 | 1715 | 1.230 |
Why?
|
| Drug Therapy, Combination | 46 | 2021 | 6309 | 1.220 |
Why?
|
| Nucleus Accumbens | 22 | 2006 | 360 | 1.220 |
Why?
|
| Adult | 211 | 2024 | 223139 | 1.160 |
Why?
|
| Puerperal Disorders | 6 | 2023 | 304 | 1.130 |
Why?
|
| Male | 377 | 2024 | 363935 | 1.120 |
Why?
|
| Fluoxetine | 12 | 2015 | 732 | 1.110 |
Why?
|
| Cyclothymic Disorder | 4 | 2019 | 42 | 1.080 |
Why?
|
| Rats | 211 | 2008 | 23717 | 1.080 |
Why?
|
| Substance Withdrawal Syndrome | 20 | 2010 | 627 | 1.040 |
Why?
|
| Ketamine | 3 | 2023 | 527 | 1.030 |
Why?
|
| Age of Onset | 18 | 2023 | 3344 | 0.980 |
Why?
|
| Oxidopamine | 14 | 2005 | 169 | 0.970 |
Why?
|
| Female | 261 | 2024 | 396233 | 0.970 |
Why?
|
| Schizophrenic Psychology | 15 | 2017 | 1646 | 0.970 |
Why?
|
| Hospitalization | 40 | 2023 | 10811 | 0.950 |
Why?
|
| Caudate Nucleus | 19 | 2006 | 388 | 0.930 |
Why?
|
| Risk Factors | 83 | 2023 | 74857 | 0.910 |
Why?
|
| Recurrence | 43 | 2016 | 8494 | 0.910 |
Why?
|
| Imipramine | 8 | 2017 | 96 | 0.910 |
Why?
|
| Haloperidol | 26 | 2023 | 394 | 0.890 |
Why?
|
| Putamen | 11 | 2006 | 288 | 0.870 |
Why?
|
| Membrane Glycoproteins | 17 | 2005 | 3692 | 0.850 |
Why?
|
| Limbic System | 14 | 1999 | 418 | 0.850 |
Why?
|
| Hyperkinesis | 7 | 2005 | 88 | 0.850 |
Why?
|
| Xanthurenates | 2 | 2019 | 6 | 0.810 |
Why?
|
| Affective Disorders, Psychotic | 7 | 2008 | 187 | 0.810 |
Why?
|
| Lithium Chloride | 2 | 2014 | 82 | 0.790 |
Why?
|
| Patient Dropouts | 3 | 2014 | 411 | 0.790 |
Why?
|
| Carbamazepine | 7 | 2018 | 224 | 0.770 |
Why?
|
| Rats, Sprague-Dawley | 54 | 2006 | 8113 | 0.760 |
Why?
|
| Placebo Effect | 4 | 2014 | 515 | 0.750 |
Why?
|
| Kynurenine | 2 | 2019 | 142 | 0.750 |
Why?
|
| Nerve Tissue Proteins | 19 | 2005 | 4399 | 0.740 |
Why?
|
| Triazines | 4 | 2018 | 311 | 0.740 |
Why?
|
| Dyskinesia, Drug-Induced | 14 | 2005 | 165 | 0.730 |
Why?
|
| Drug Utilization | 6 | 2010 | 1187 | 0.730 |
Why?
|
| Treatment Outcome | 80 | 2019 | 65219 | 0.720 |
Why?
|
| Substance-Related Disorders | 14 | 2023 | 4418 | 0.720 |
Why?
|
| Motor Activity | 37 | 2012 | 2711 | 0.710 |
Why?
|
| Dopamine Agents | 16 | 2013 | 186 | 0.710 |
Why?
|
| Drug Administration Schedule | 32 | 2015 | 4853 | 0.710 |
Why?
|
| Tryptophan | 7 | 2019 | 483 | 0.700 |
Why?
|
| Alopecia | 2 | 2021 | 415 | 0.690 |
Why?
|
| Secondary Prevention | 12 | 2015 | 1470 | 0.690 |
Why?
|
| Drug Therapy | 5 | 2016 | 504 | 0.670 |
Why?
|
| Appetite | 1 | 2022 | 247 | 0.670 |
Why?
|
| Middle Aged | 131 | 2024 | 223083 | 0.660 |
Why?
|
| Dose-Response Relationship, Drug | 63 | 2021 | 10737 | 0.640 |
Why?
|
| Brain Chemistry | 24 | 2006 | 951 | 0.630 |
Why?
|
| Movement Disorders | 8 | 2011 | 461 | 0.620 |
Why?
|
| Chlorpromazine | 11 | 2017 | 111 | 0.620 |
Why?
|
| Carrier Proteins | 16 | 2004 | 4910 | 0.620 |
Why?
|
| Dibenzothiazepines | 6 | 2003 | 102 | 0.610 |
Why?
|
| Receptors, Dopamine D4 | 18 | 2004 | 168 | 0.610 |
Why?
|
| Community Mental Health Centers | 1 | 2018 | 93 | 0.600 |
Why?
|
| Neostriatum | 8 | 2004 | 231 | 0.590 |
Why?
|
| Autoradiography | 20 | 2006 | 723 | 0.590 |
Why?
|
| Antidepressive Agents, Second-Generation | 4 | 2014 | 490 | 0.590 |
Why?
|
| Pregnancy Complications | 9 | 2018 | 2970 | 0.580 |
Why?
|
| Cocaine | 19 | 2008 | 944 | 0.570 |
Why?
|
| Brain | 105 | 2018 | 27177 | 0.560 |
Why?
|
| Prevalence | 25 | 2023 | 15827 | 0.550 |
Why?
|
| Risk | 20 | 2021 | 9599 | 0.550 |
Why?
|
| Crisis Intervention | 1 | 2017 | 111 | 0.540 |
Why?
|
| Goals | 1 | 2022 | 717 | 0.540 |
Why?
|
| Time Factors | 66 | 2024 | 40108 | 0.540 |
Why?
|
| Quinolones | 3 | 2005 | 389 | 0.540 |
Why?
|
| Meta-Analysis as Topic | 6 | 2023 | 1366 | 0.530 |
Why?
|
| Patient Compliance | 5 | 2008 | 2694 | 0.530 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 15 | 2018 | 3719 | 0.530 |
Why?
|
| Law Enforcement | 1 | 2017 | 112 | 0.520 |
Why?
|
| Multivariate Analysis | 13 | 2016 | 12061 | 0.520 |
Why?
|
| Schizophrenia, Paranoid | 2 | 2016 | 102 | 0.510 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 305 | 0.510 |
Why?
|
| Morbidity | 7 | 2021 | 1753 | 0.510 |
Why?
|
| Affective Symptoms | 5 | 2016 | 418 | 0.510 |
Why?
|
| Spinal Dysraphism | 1 | 2018 | 179 | 0.500 |
Why?
|
| Violence | 3 | 2017 | 931 | 0.500 |
Why?
|
| Neural Tube Defects | 1 | 2018 | 256 | 0.500 |
Why?
|
| Comorbidity | 20 | 2019 | 10579 | 0.500 |
Why?
|
| Police | 1 | 2017 | 158 | 0.500 |
Why?
|
| Periodicity | 4 | 2008 | 347 | 0.500 |
Why?
|
| Tetrahydronaphthalenes | 14 | 1998 | 84 | 0.500 |
Why?
|
| Weight Gain | 2 | 2022 | 2356 | 0.490 |
Why?
|
| Alkylating Agents | 5 | 2000 | 133 | 0.490 |
Why?
|
| Receptors, Glutamate | 4 | 2003 | 228 | 0.490 |
Why?
|
| Delayed-Action Preparations | 7 | 2023 | 966 | 0.480 |
Why?
|
| Radioligand Assay | 25 | 2008 | 365 | 0.470 |
Why?
|
| Norepinephrine | 37 | 2002 | 898 | 0.470 |
Why?
|
| Epilepsy | 6 | 2014 | 3317 | 0.470 |
Why?
|
| Amphetamine | 12 | 2000 | 222 | 0.470 |
Why?
|
| Animals, Newborn | 12 | 2005 | 2677 | 0.470 |
Why?
|
| Age Factors | 32 | 2018 | 18386 | 0.460 |
Why?
|
| Animals | 252 | 2021 | 168800 | 0.460 |
Why?
|
| Piperazines | 7 | 2005 | 2547 | 0.460 |
Why?
|
| Monoamine Oxidase Inhibitors | 13 | 2012 | 152 | 0.460 |
Why?
|
| Anxiety | 7 | 2023 | 4672 | 0.460 |
Why?
|
| Capgras Syndrome | 1 | 2014 | 10 | 0.460 |
Why?
|
| Adrenergic Uptake Inhibitors | 5 | 2008 | 187 | 0.460 |
Why?
|
| Longitudinal Studies | 16 | 2022 | 14747 | 0.450 |
Why?
|
| Rats, Inbred Strains | 46 | 1992 | 2077 | 0.450 |
Why?
|
| Menarche | 1 | 2016 | 532 | 0.440 |
Why?
|
| History, 19th Century | 11 | 2017 | 711 | 0.440 |
Why?
|
| Psychopathology | 4 | 2018 | 434 | 0.440 |
Why?
|
| Dopamine Agonists | 7 | 2012 | 346 | 0.440 |
Why?
|
| Basal Ganglia Diseases | 5 | 2011 | 145 | 0.440 |
Why?
|
| Publishing | 3 | 2013 | 836 | 0.430 |
Why?
|
| Thiophenes | 2 | 2009 | 570 | 0.430 |
Why?
|
| Arsenic | 1 | 2017 | 357 | 0.430 |
Why?
|
| Dermatitis, Atopic | 1 | 2020 | 724 | 0.430 |
Why?
|
| Severity of Illness Index | 25 | 2020 | 15882 | 0.420 |
Why?
|
| Drug Prescriptions | 7 | 2020 | 1662 | 0.420 |
Why?
|
| Probiotics | 1 | 2017 | 387 | 0.410 |
Why?
|
| Psoriasis | 1 | 2020 | 922 | 0.410 |
Why?
|
| Hydroxyindoleacetic Acid | 11 | 2019 | 94 | 0.400 |
Why?
|
| Young Adult | 31 | 2023 | 59868 | 0.400 |
Why?
|
| Adolescent | 58 | 2023 | 88819 | 0.400 |
Why?
|
| Recovery of Function | 5 | 2010 | 2971 | 0.400 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 13 | 2008 | 326 | 0.400 |
Why?
|
| Stereotyped Behavior | 24 | 2001 | 133 | 0.400 |
Why?
|
| Self-Injurious Behavior | 2 | 2015 | 572 | 0.390 |
Why?
|
| Desipramine | 20 | 2005 | 183 | 0.390 |
Why?
|
| Stereoisomerism | 30 | 2008 | 612 | 0.390 |
Why?
|
| Clinical Trials as Topic | 17 | 2019 | 8038 | 0.380 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 17 | 2006 | 410 | 0.380 |
Why?
|
| Follow-Up Studies | 35 | 2018 | 39243 | 0.380 |
Why?
|
| Folic Acid | 2 | 2018 | 1337 | 0.370 |
Why?
|
| Reproductive Behavior | 1 | 2011 | 27 | 0.360 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 1805 | 0.360 |
Why?
|
| Survival Analysis | 19 | 2022 | 10087 | 0.360 |
Why?
|
| Sex Factors | 23 | 2020 | 10614 | 0.360 |
Why?
|
| Benzothiazoles | 1 | 2011 | 245 | 0.360 |
Why?
|
| Cause of Death | 5 | 2017 | 3715 | 0.350 |
Why?
|
| Behavior, Animal | 24 | 1994 | 1867 | 0.350 |
Why?
|
| Tropanes | 8 | 2006 | 47 | 0.350 |
Why?
|
| Structure-Activity Relationship | 34 | 2008 | 3051 | 0.350 |
Why?
|
| Somatoform Disorders | 1 | 2013 | 425 | 0.350 |
Why?
|
| Biological Clocks | 1 | 2012 | 319 | 0.350 |
Why?
|
| Withholding Treatment | 1 | 2014 | 619 | 0.350 |
Why?
|
| Tritium | 35 | 2002 | 702 | 0.340 |
Why?
|
| Receptors, Serotonin | 7 | 2002 | 209 | 0.340 |
Why?
|
| Benzazepines | 7 | 2003 | 308 | 0.340 |
Why?
|
| Phenothiazines | 4 | 2008 | 60 | 0.340 |
Why?
|
| Neuropsychological Tests | 6 | 2018 | 7119 | 0.340 |
Why?
|
| Cognition Disorders | 6 | 2010 | 3966 | 0.330 |
Why?
|
| Research Report | 1 | 2013 | 367 | 0.330 |
Why?
|
| Polypharmacy | 3 | 2010 | 307 | 0.330 |
Why?
|
| Sympatholytics | 6 | 2001 | 82 | 0.330 |
Why?
|
| Birth Rate | 1 | 2011 | 168 | 0.330 |
Why?
|
| Thinking | 2 | 2017 | 320 | 0.330 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 168 | 0.320 |
Why?
|
| Psychometrics | 3 | 2018 | 3060 | 0.320 |
Why?
|
| Siblings | 1 | 2013 | 828 | 0.320 |
Why?
|
| Circadian Rhythm | 11 | 2012 | 2594 | 0.320 |
Why?
|
| Child | 40 | 2023 | 80573 | 0.320 |
Why?
|
| Cross-Cultural Comparison | 2 | 2010 | 636 | 0.320 |
Why?
|
| Asia | 6 | 2020 | 630 | 0.320 |
Why?
|
| Panic Disorder | 3 | 2014 | 613 | 0.320 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2015 | 451 | 0.310 |
Why?
|
| Fatty Acids | 1 | 2017 | 1805 | 0.310 |
Why?
|
| Selection, Genetic | 1 | 2013 | 877 | 0.310 |
Why?
|
| Synaptosomes | 22 | 2000 | 116 | 0.310 |
Why?
|
| Argentina | 4 | 2015 | 249 | 0.310 |
Why?
|
| Personality Inventory | 5 | 2021 | 1019 | 0.310 |
Why?
|
| Bupropion | 2 | 2003 | 303 | 0.310 |
Why?
|
| Substantia Nigra | 5 | 2001 | 346 | 0.300 |
Why?
|
| International Cooperation | 3 | 2010 | 1433 | 0.300 |
Why?
|
| Risk Assessment | 21 | 2019 | 24276 | 0.300 |
Why?
|
| Bayes Theorem | 6 | 2016 | 2353 | 0.300 |
Why?
|
| Patient Discharge | 4 | 2019 | 3465 | 0.300 |
Why?
|
| Neurosyphilis | 1 | 2008 | 27 | 0.290 |
Why?
|
| Convalescence | 1 | 2008 | 107 | 0.290 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 368 | 0.290 |
Why?
|
| Length of Stay | 9 | 2016 | 6490 | 0.290 |
Why?
|
| Attitude to Health | 3 | 2014 | 2020 | 0.290 |
Why?
|
| Perinatal Care | 1 | 2010 | 244 | 0.290 |
Why?
|
| Double-Blind Method | 17 | 2017 | 12426 | 0.280 |
Why?
|
| History, 20th Century | 11 | 2017 | 2762 | 0.280 |
Why?
|
| Chronobiology Disorders | 1 | 2008 | 73 | 0.280 |
Why?
|
| Tyrosine 3-Monooxygenase | 12 | 2005 | 367 | 0.280 |
Why?
|
| Placebos | 8 | 2013 | 1659 | 0.280 |
Why?
|
| Piracetam | 1 | 2007 | 88 | 0.270 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 4 | 2003 | 50 | 0.270 |
Why?
|
| Fluphenazine | 8 | 2006 | 35 | 0.270 |
Why?
|
| Ecology | 1 | 2007 | 105 | 0.270 |
Why?
|
| Mental Health | 2 | 2018 | 3273 | 0.270 |
Why?
|
| Akathisia, Drug-Induced | 2 | 2006 | 66 | 0.270 |
Why?
|
| Abnormalities, Drug-Induced | 3 | 2007 | 336 | 0.270 |
Why?
|
| Logistic Models | 9 | 2018 | 13273 | 0.270 |
Why?
|
| Prospective Studies | 25 | 2023 | 54812 | 0.260 |
Why?
|
| Malaria, Cerebral | 1 | 2008 | 136 | 0.260 |
Why?
|
| Accidents | 1 | 2007 | 164 | 0.260 |
Why?
|
| Dihydroxyphenylalanine | 15 | 1994 | 74 | 0.260 |
Why?
|
| Nootropic Agents | 1 | 2007 | 159 | 0.260 |
Why?
|
| Symporters | 5 | 2005 | 362 | 0.260 |
Why?
|
| Salts | 2 | 2024 | 60 | 0.260 |
Why?
|
| Demography | 5 | 2015 | 1641 | 0.260 |
Why?
|
| Antioxidants | 2 | 2011 | 1671 | 0.260 |
Why?
|
| Research Design | 8 | 2018 | 6206 | 0.260 |
Why?
|
| Overweight | 3 | 2021 | 2444 | 0.260 |
Why?
|
| Drug Labeling | 2 | 2009 | 251 | 0.250 |
Why?
|
| Psychological Theory | 3 | 2011 | 172 | 0.250 |
Why?
|
| Family Characteristics | 1 | 2011 | 1001 | 0.250 |
Why?
|
| Drug Tolerance | 5 | 2019 | 365 | 0.250 |
Why?
|
| Catecholamines | 16 | 1991 | 388 | 0.250 |
Why?
|
| Irritable Mood | 4 | 2021 | 196 | 0.250 |
Why?
|
| Leukopenia | 5 | 2015 | 213 | 0.240 |
Why?
|
| Sex Distribution | 6 | 2015 | 2270 | 0.240 |
Why?
|
| Receptors, Kainic Acid | 4 | 2004 | 91 | 0.240 |
Why?
|
| S-Adenosylmethionine | 11 | 1987 | 219 | 0.240 |
Why?
|
| Denervation | 6 | 2001 | 265 | 0.240 |
Why?
|
| GTP-Binding Proteins | 2 | 2000 | 945 | 0.240 |
Why?
|
| Methionine | 16 | 1979 | 569 | 0.240 |
Why?
|
| Coffee | 1 | 2009 | 593 | 0.240 |
Why?
|
| Spiperone | 8 | 1999 | 31 | 0.230 |
Why?
|
| Long-Term Care | 8 | 2008 | 630 | 0.230 |
Why?
|
| Cross-Sectional Studies | 16 | 2024 | 26290 | 0.230 |
Why?
|
| Neurology | 2 | 2010 | 784 | 0.230 |
Why?
|
| Kainic Acid | 3 | 1999 | 204 | 0.230 |
Why?
|
| Marijuana Abuse | 1 | 2008 | 409 | 0.230 |
Why?
|
| Obsessive-Compulsive Disorder | 4 | 2008 | 1495 | 0.230 |
Why?
|
| Postpartum Period | 1 | 2011 | 1195 | 0.230 |
Why?
|
| Retrospective Studies | 27 | 2023 | 81565 | 0.230 |
Why?
|
| Germany | 6 | 2016 | 882 | 0.230 |
Why?
|
| Quinolines | 5 | 2000 | 769 | 0.230 |
Why?
|
| Prognosis | 17 | 2018 | 29912 | 0.230 |
Why?
|
| Philosophy | 1 | 2004 | 69 | 0.220 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 414 | 0.220 |
Why?
|
| Naphthalenes | 5 | 1988 | 197 | 0.220 |
Why?
|
| Delusions | 6 | 2021 | 300 | 0.220 |
Why?
|
| Extrapyramidal Tracts | 4 | 2002 | 17 | 0.220 |
Why?
|
| Disease Progression | 8 | 2024 | 13616 | 0.220 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2004 | 904 | 0.220 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 2068 | 0.220 |
Why?
|
| Receptors, AMPA | 4 | 2004 | 335 | 0.220 |
Why?
|
| Disability Evaluation | 2 | 2010 | 1824 | 0.220 |
Why?
|
| Prolactin | 3 | 2011 | 626 | 0.220 |
Why?
|
| Piperidines | 8 | 2006 | 1664 | 0.210 |
Why?
|
| Combined Modality Therapy | 7 | 2015 | 8525 | 0.210 |
Why?
|
| Arousal | 8 | 2013 | 1174 | 0.210 |
Why?
|
| Hippocampus | 9 | 2006 | 3773 | 0.210 |
Why?
|
| Incidence | 11 | 2019 | 21513 | 0.210 |
Why?
|
| Acute Disease | 13 | 2011 | 7237 | 0.210 |
Why?
|
| Pregnancy | 15 | 2018 | 30233 | 0.210 |
Why?
|
| Treatment Refusal | 3 | 2002 | 433 | 0.200 |
Why?
|
| Cognition | 3 | 2013 | 7050 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2018 | 4544 | 0.200 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 3930 | 0.200 |
Why?
|
| Adrenergic Agents | 4 | 2005 | 72 | 0.200 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2009 | 1568 | 0.200 |
Why?
|
| Sympathectomy, Chemical | 1 | 2001 | 25 | 0.200 |
Why?
|
| Psychotherapy | 5 | 2023 | 1648 | 0.200 |
Why?
|
| Thyroid Hormones | 2 | 2012 | 408 | 0.190 |
Why?
|
| Outpatients | 4 | 2014 | 1596 | 0.190 |
Why?
|
| Europe | 5 | 2013 | 3430 | 0.190 |
Why?
|
| Databases, Bibliographic | 2 | 2015 | 128 | 0.190 |
Why?
|
| Parasympatholytics | 5 | 1992 | 89 | 0.190 |
Why?
|
| 5-Hydroxytryptophan | 9 | 1980 | 33 | 0.190 |
Why?
|
| Electroconvulsive Therapy | 7 | 2012 | 505 | 0.190 |
Why?
|
| Interview, Psychological | 3 | 2011 | 811 | 0.190 |
Why?
|
| Child Psychiatry | 1 | 2004 | 230 | 0.190 |
Why?
|
| Biogenic Amines | 7 | 2004 | 53 | 0.190 |
Why?
|
| Neurotoxins | 2 | 2003 | 240 | 0.190 |
Why?
|
| Sertraline | 3 | 1999 | 210 | 0.190 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 7 | 2006 | 66 | 0.180 |
Why?
|
| Central Nervous System Stimulants | 4 | 2004 | 1167 | 0.180 |
Why?
|
| Striatonigral Degeneration | 1 | 2000 | 13 | 0.180 |
Why?
|
| Aged | 46 | 2018 | 171219 | 0.180 |
Why?
|
| Inpatients | 5 | 2016 | 2566 | 0.180 |
Why?
|
| Antimalarials | 1 | 2008 | 909 | 0.180 |
Why?
|
| Prefrontal Cortex | 5 | 2000 | 2224 | 0.180 |
Why?
|
| Binding, Competitive | 15 | 2008 | 1140 | 0.180 |
Why?
|
| Visual Cortex | 2 | 1999 | 1081 | 0.180 |
Why?
|
| Alcoholism | 2 | 2008 | 1979 | 0.180 |
Why?
|
| Synaptic Transmission | 11 | 2004 | 1175 | 0.180 |
Why?
|
| Spain | 5 | 2013 | 483 | 0.180 |
Why?
|
| Drug Interactions | 14 | 2001 | 1419 | 0.180 |
Why?
|
| Biogenic Monoamines | 3 | 2004 | 50 | 0.180 |
Why?
|
| Nervous System Diseases | 5 | 2018 | 1657 | 0.170 |
Why?
|
| Presynaptic Terminals | 1 | 2002 | 299 | 0.170 |
Why?
|
| Dexamethasone | 8 | 1988 | 1962 | 0.170 |
Why?
|
| Receptors, Dopamine D3 | 7 | 2001 | 106 | 0.170 |
Why?
|
| Hydrocortisone | 9 | 2015 | 1832 | 0.170 |
Why?
|
| Long QT Syndrome | 1 | 2004 | 474 | 0.170 |
Why?
|
| Mental Health Services | 3 | 2017 | 1729 | 0.170 |
Why?
|
| Biological Psychiatry | 1 | 1999 | 27 | 0.170 |
Why?
|
| Receptors, GABA-B | 1 | 2000 | 59 | 0.170 |
Why?
|
| Thiazoles | 2 | 2004 | 1528 | 0.170 |
Why?
|
| Drugs, Investigational | 1 | 2002 | 211 | 0.170 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 911 | 0.170 |
Why?
|
| Ergolines | 3 | 1994 | 55 | 0.170 |
Why?
|
| Dihydroxytryptamines | 4 | 1980 | 6 | 0.160 |
Why?
|
| Catalepsy | 9 | 2001 | 31 | 0.160 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2000 | 80 | 0.160 |
Why?
|
| Mass Screening | 2 | 2018 | 5450 | 0.160 |
Why?
|
| Nerve Endings | 10 | 2002 | 103 | 0.160 |
Why?
|
| Sex Offenses | 1 | 2023 | 355 | 0.160 |
Why?
|
| Amines | 7 | 1988 | 281 | 0.160 |
Why?
|
| Urban Population | 2 | 2021 | 2040 | 0.160 |
Why?
|
| Quinolinic Acid | 1 | 2019 | 67 | 0.160 |
Why?
|
| Kynurenic Acid | 1 | 2019 | 44 | 0.160 |
Why?
|
| Neurotransmitter Agents | 11 | 1983 | 661 | 0.160 |
Why?
|
| Kinetics | 27 | 2008 | 6273 | 0.160 |
Why?
|
| Iodine Radioisotopes | 4 | 2008 | 1029 | 0.160 |
Why?
|
| Hallucinations | 3 | 2014 | 373 | 0.160 |
Why?
|
| History, 18th Century | 2 | 2017 | 206 | 0.160 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2001 | 391 | 0.160 |
Why?
|
| Attitude of Health Personnel | 2 | 2010 | 3928 | 0.150 |
Why?
|
| Cerebral Cortex | 19 | 2006 | 5758 | 0.150 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2003 | 391 | 0.150 |
Why?
|
| Methylphenidate | 2 | 2001 | 481 | 0.150 |
Why?
|
| Hypothyroidism | 1 | 2023 | 665 | 0.150 |
Why?
|
| Clorgyline | 1 | 1997 | 13 | 0.150 |
Why?
|
| Amides | 1 | 2001 | 451 | 0.150 |
Why?
|
| Pharmacoepidemiology | 5 | 2024 | 351 | 0.150 |
Why?
|
| Analysis of Variance | 9 | 2012 | 6208 | 0.150 |
Why?
|
| Self Concept | 2 | 2016 | 1040 | 0.150 |
Why?
|
| Selegiline | 1 | 1997 | 31 | 0.150 |
Why?
|
| Analgesics | 3 | 2013 | 1067 | 0.150 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 1998 | 107 | 0.150 |
Why?
|
| Memory, Short-Term | 1 | 2004 | 1002 | 0.150 |
Why?
|
| Gender Identity | 1 | 2023 | 766 | 0.140 |
Why?
|
| Nerve Degeneration | 3 | 1999 | 748 | 0.140 |
Why?
|
| Massachusetts | 6 | 2016 | 8882 | 0.140 |
Why?
|
| Molecular Structure | 10 | 2007 | 1881 | 0.140 |
Why?
|
| Colorado | 1 | 2017 | 167 | 0.140 |
Why?
|
| Research | 2 | 2005 | 1975 | 0.140 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2021 | 364 | 0.140 |
Why?
|
| Tryptamines | 6 | 1979 | 93 | 0.140 |
Why?
|
| Rorschach Test | 1 | 2017 | 26 | 0.140 |
Why?
|
| Prostatic Hyperplasia | 1 | 2021 | 514 | 0.140 |
Why?
|
| Marital Status | 2 | 2017 | 426 | 0.140 |
Why?
|
| Tissue Banks | 1 | 2018 | 183 | 0.140 |
Why?
|
| 5,7-Dihydroxytryptamine | 4 | 1980 | 13 | 0.140 |
Why?
|
| Diagnosis | 1 | 2018 | 157 | 0.140 |
Why?
|
| Entorhinal Cortex | 3 | 2006 | 285 | 0.140 |
Why?
|
| Neuronal Plasticity | 2 | 2002 | 1447 | 0.140 |
Why?
|
| Linear Models | 4 | 2015 | 5873 | 0.130 |
Why?
|
| Infertility, Female | 1 | 2002 | 763 | 0.130 |
Why?
|
| ROC Curve | 2 | 2014 | 3614 | 0.130 |
Why?
|
| Advisory Committees | 4 | 2019 | 796 | 0.130 |
Why?
|
| Cyclic AMP | 10 | 1990 | 1467 | 0.130 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 3432 | 0.130 |
Why?
|
| Agranulocytosis | 2 | 2015 | 98 | 0.130 |
Why?
|
| Episode of Care | 2 | 2013 | 127 | 0.130 |
Why?
|
| United States | 20 | 2011 | 72920 | 0.130 |
Why?
|
| Registries | 2 | 2015 | 8347 | 0.130 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 2008 | 1143 | 0.130 |
Why?
|
| Evidence-Based Medicine | 3 | 2014 | 3690 | 0.120 |
Why?
|
| Methyltransferases | 8 | 1978 | 373 | 0.120 |
Why?
|
| Water Supply | 1 | 2017 | 204 | 0.120 |
Why?
|
| Diagnostic Errors | 3 | 2013 | 1276 | 0.120 |
Why?
|
| International Classification of Diseases | 3 | 2013 | 934 | 0.120 |
Why?
|
| Patient Admission | 3 | 2005 | 1365 | 0.120 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 4 | 2002 | 61 | 0.120 |
Why?
|
| Dysthymic Disorder | 2 | 2010 | 73 | 0.120 |
Why?
|
| Benzamides | 5 | 2003 | 1376 | 0.120 |
Why?
|
| Benztropine | 3 | 1991 | 17 | 0.120 |
Why?
|
| Off-Label Use | 3 | 2014 | 185 | 0.120 |
Why?
|
| Affect | 3 | 2013 | 1494 | 0.120 |
Why?
|
| Socioeconomic Factors | 6 | 2013 | 7843 | 0.120 |
Why?
|
| Drug Combinations | 2 | 2015 | 2076 | 0.120 |
Why?
|
| Stress, Psychological | 3 | 2015 | 4527 | 0.120 |
Why?
|
| Aging | 9 | 2003 | 8723 | 0.120 |
Why?
|
| Obesity | 3 | 2006 | 13085 | 0.120 |
Why?
|
| Receptors, sigma | 5 | 1995 | 46 | 0.120 |
Why?
|
| Behavioral Symptoms | 1 | 2016 | 187 | 0.120 |
Why?
|
| Weight Loss | 1 | 2006 | 2711 | 0.120 |
Why?
|
| Radiopharmaceuticals | 4 | 2008 | 2702 | 0.120 |
Why?
|
| Molecular Probes | 2 | 1996 | 309 | 0.110 |
Why?
|
| Injections | 4 | 2020 | 839 | 0.110 |
Why?
|
| Steroids | 1 | 2019 | 934 | 0.110 |
Why?
|
| Physician-Patient Relations | 2 | 2022 | 3270 | 0.110 |
Why?
|
| Docosahexaenoic Acids | 1 | 2001 | 916 | 0.110 |
Why?
|
| Memantine | 1 | 2015 | 110 | 0.110 |
Why?
|
| Myoclonus | 4 | 1979 | 107 | 0.110 |
Why?
|
| Family Health | 3 | 2015 | 1253 | 0.110 |
Why?
|
| Human Development | 1 | 2014 | 122 | 0.110 |
Why?
|
| Ligands | 11 | 2007 | 3274 | 0.110 |
Why?
|
| Age Distribution | 3 | 2015 | 2865 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2005 | 2084 | 0.110 |
Why?
|
| Child Behavior | 1 | 2019 | 864 | 0.110 |
Why?
|
| Research Support as Topic | 1 | 1998 | 697 | 0.110 |
Why?
|
| Sculpture | 1 | 2013 | 5 | 0.110 |
Why?
|
| Homicide | 1 | 2016 | 294 | 0.110 |
Why?
|
| Chronic Disease | 8 | 2010 | 9354 | 0.110 |
Why?
|
| Delirium | 4 | 2003 | 1699 | 0.110 |
Why?
|
| Receptors, Muscarinic | 3 | 1988 | 156 | 0.100 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 1985 | 1140 | 0.100 |
Why?
|
| Neuroprotective Agents | 1 | 1999 | 959 | 0.100 |
Why?
|
| Research Personnel | 1 | 1998 | 589 | 0.100 |
Why?
|
| Borderline Personality Disorder | 1 | 2020 | 767 | 0.100 |
Why?
|
| Emotions | 2 | 2016 | 2758 | 0.100 |
Why?
|
| Pyridines | 6 | 2004 | 2889 | 0.100 |
Why?
|
| Receptors, Opioid | 2 | 1991 | 145 | 0.100 |
Why?
|
| Diagnosis, Differential | 13 | 2012 | 12976 | 0.100 |
Why?
|
| Databases, Factual | 4 | 2014 | 8062 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2018 | 1186 | 0.100 |
Why?
|
| Risk Adjustment | 1 | 2016 | 597 | 0.100 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2016 | 497 | 0.100 |
Why?
|
| Hospitals, University | 2 | 2016 | 573 | 0.100 |
Why?
|
| Rhenium | 3 | 2002 | 13 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2011 | 1729 | 0.100 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 6 | 1998 | 60 | 0.100 |
Why?
|
| Smoking | 1 | 2009 | 9082 | 0.100 |
Why?
|
| Tranquilizing Agents | 5 | 1977 | 59 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2017 | 8724 | 0.100 |
Why?
|
| Drug Synergism | 6 | 2011 | 1754 | 0.100 |
Why?
|
| Alzheimer Disease | 3 | 2007 | 8724 | 0.100 |
Why?
|
| Behavior | 4 | 1977 | 537 | 0.100 |
Why?
|
| Forecasting | 2 | 2014 | 2936 | 0.100 |
Why?
|
| Receptors, Drug | 6 | 1979 | 156 | 0.100 |
Why?
|
| Thioridazine | 6 | 1995 | 33 | 0.100 |
Why?
|
| Benzomorphans | 1 | 1991 | 5 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 1999 | 1790 | 0.100 |
Why?
|
| Administration, Oral | 10 | 2010 | 4016 | 0.100 |
Why?
|
| Acculturation | 1 | 2013 | 179 | 0.100 |
Why?
|
| Esters | 5 | 2008 | 213 | 0.100 |
Why?
|
| Hepatic Encephalopathy | 5 | 1977 | 143 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 8 | 2008 | 1527 | 0.090 |
Why?
|
| Homovanillic Acid | 4 | 1998 | 73 | 0.090 |
Why?
|
| Nomifensine | 1 | 1991 | 14 | 0.090 |
Why?
|
| Triage | 1 | 2018 | 994 | 0.090 |
Why?
|
| Central Nervous System | 7 | 1978 | 1343 | 0.090 |
Why?
|
| Employment | 1 | 2017 | 1108 | 0.090 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2015 | 702 | 0.090 |
Why?
|
| Troponin I | 1 | 2015 | 656 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 1184 | 0.090 |
Why?
|
| Neurotensin | 1 | 1991 | 59 | 0.090 |
Why?
|
| Amygdala | 2 | 1998 | 1376 | 0.090 |
Why?
|
| Guilt | 1 | 2011 | 92 | 0.090 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 2 | 2008 | 58 | 0.090 |
Why?
|
| Causality | 1 | 2016 | 1247 | 0.090 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 2 | 1988 | 32 | 0.090 |
Why?
|
| Perception | 1 | 2017 | 1204 | 0.090 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2005 | 134 | 0.090 |
Why?
|
| Publication Bias | 1 | 2011 | 157 | 0.090 |
Why?
|
| Thyroid Gland | 1 | 1997 | 1168 | 0.090 |
Why?
|
| Phenethylamines | 6 | 1981 | 95 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2016 | 961 | 0.090 |
Why?
|
| Association | 1 | 2010 | 53 | 0.090 |
Why?
|
| Predictive Value of Tests | 6 | 2015 | 15403 | 0.080 |
Why?
|
| Prescriptions | 2 | 2023 | 388 | 0.080 |
Why?
|
| Stimulation, Chemical | 7 | 1996 | 303 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2013 | 893 | 0.080 |
Why?
|
| Paroxetine | 3 | 2000 | 181 | 0.080 |
Why?
|
| Behavior Therapy | 2 | 2012 | 886 | 0.080 |
Why?
|
| Canada | 2 | 2014 | 2120 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2002 | 3617 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 3 | 2007 | 1193 | 0.080 |
Why?
|
| Neutropenia | 1 | 2015 | 894 | 0.080 |
Why?
|
| General Practitioners | 1 | 2011 | 105 | 0.080 |
Why?
|
| Republic of Korea | 1 | 2011 | 591 | 0.080 |
Why?
|
| Chemical Phenomena | 8 | 2002 | 483 | 0.080 |
Why?
|
| Neurosciences | 1 | 2014 | 385 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2015 | 1592 | 0.080 |
Why?
|
| Physostigmine | 3 | 1979 | 50 | 0.080 |
Why?
|
| Psychiatric Department, Hospital | 1 | 2010 | 133 | 0.080 |
Why?
|
| Phototherapy | 1 | 2012 | 369 | 0.080 |
Why?
|
| Residence Characteristics | 2 | 2011 | 2116 | 0.080 |
Why?
|
| Lactation | 2 | 2009 | 391 | 0.080 |
Why?
|
| Single-Blind Method | 1 | 2013 | 1588 | 0.080 |
Why?
|
| Calcium Channel Blockers | 1 | 2012 | 686 | 0.080 |
Why?
|
| Odds Ratio | 5 | 2009 | 9657 | 0.080 |
Why?
|
| Statistics as Topic | 2 | 2017 | 2351 | 0.080 |
Why?
|
| Adenosine | 2 | 1990 | 813 | 0.080 |
Why?
|
| Sexuality | 1 | 2011 | 179 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2021 | 2190 | 0.080 |
Why?
|
| Tissue Distribution | 3 | 2006 | 2271 | 0.080 |
Why?
|
| Indicators and Reagents | 6 | 2006 | 456 | 0.080 |
Why?
|
| Monoamine Oxidase | 6 | 1986 | 179 | 0.080 |
Why?
|
| Isotope Labeling | 2 | 2008 | 390 | 0.080 |
Why?
|
| Decision Making | 1 | 2002 | 3955 | 0.080 |
Why?
|
| Psychomotor Performance | 2 | 2009 | 1885 | 0.080 |
Why?
|
| Translations | 3 | 2004 | 84 | 0.080 |
Why?
|
| Disease Models, Animal | 6 | 2005 | 18321 | 0.080 |
Why?
|
| Health Care Costs | 2 | 2016 | 3243 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 4 | 2005 | 361 | 0.080 |
Why?
|
| Organ Specificity | 4 | 1998 | 1966 | 0.080 |
Why?
|
| Tyrosine | 7 | 1990 | 1427 | 0.080 |
Why?
|
| Reserpine | 7 | 1994 | 63 | 0.080 |
Why?
|
| Microinjections | 3 | 1998 | 319 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 5510 | 0.080 |
Why?
|
| Half-Life | 6 | 1993 | 645 | 0.080 |
Why?
|
| Patient Care Planning | 1 | 2013 | 903 | 0.070 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2005 | 300 | 0.070 |
Why?
|
| Electroencephalography | 3 | 2008 | 6279 | 0.070 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 3 | 2002 | 41 | 0.070 |
Why?
|
| Heart Rate | 3 | 2015 | 4204 | 0.070 |
Why?
|
| Carbohydrates | 1 | 2010 | 387 | 0.070 |
Why?
|
| Tomography, Emission-Computed | 3 | 2002 | 1006 | 0.070 |
Why?
|
| Body Weight | 4 | 2007 | 4626 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2006 | 2915 | 0.070 |
Why?
|
| Cattle | 14 | 1990 | 3801 | 0.070 |
Why?
|
| Aftercare | 1 | 2013 | 915 | 0.070 |
Why?
|
| Chemistry | 7 | 1990 | 325 | 0.070 |
Why?
|
| Social Adjustment | 1 | 2010 | 634 | 0.070 |
Why?
|
| Endocrine System Diseases | 1 | 2009 | 244 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 1195 | 0.070 |
Why?
|
| Organometallic Compounds | 2 | 2002 | 645 | 0.070 |
Why?
|
| Alkylation | 4 | 2004 | 84 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 3606 | 0.070 |
Why?
|
| Pituitary-Adrenal System | 2 | 2015 | 553 | 0.070 |
Why?
|
| Neurotransmitter Transport Proteins | 1 | 2006 | 3 | 0.070 |
Why?
|
| Aged, 80 and over | 9 | 2011 | 59515 | 0.070 |
Why?
|
| Neurons | 7 | 2006 | 9521 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2001 | 3230 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2014 | 2332 | 0.070 |
Why?
|
| Radioimmunoassay | 5 | 1994 | 860 | 0.070 |
Why?
|
| Liver | 18 | 1988 | 7559 | 0.070 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 1735 | 0.070 |
Why?
|
| Octopamine | 5 | 1972 | 43 | 0.070 |
Why?
|
| Microspheres | 1 | 2010 | 773 | 0.070 |
Why?
|
| Cations | 1 | 1987 | 239 | 0.070 |
Why?
|
| Cross Infection | 1 | 2016 | 1427 | 0.070 |
Why?
|
| Emigrants and Immigrants | 1 | 2013 | 550 | 0.070 |
Why?
|
| Databases as Topic | 1 | 2008 | 472 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2010 | 12529 | 0.070 |
Why?
|
| Citalopram | 1 | 2009 | 402 | 0.070 |
Why?
|
| Dextroamphetamine | 4 | 1988 | 132 | 0.070 |
Why?
|
| Alcoholic Intoxication | 1 | 2007 | 171 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2662 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 5531 | 0.060 |
Why?
|
| Fertility | 1 | 2011 | 770 | 0.060 |
Why?
|
| Ambulatory Care | 6 | 2003 | 2778 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 2009 | 2227 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2006 | 5367 | 0.060 |
Why?
|
| MEDLINE | 3 | 1995 | 119 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2017 | 3561 | 0.060 |
Why?
|
| Population Density | 1 | 2006 | 193 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 3 | 1987 | 1478 | 0.060 |
Why?
|
| Mortality | 1 | 2017 | 2911 | 0.060 |
Why?
|
| United States Food and Drug Administration | 3 | 2009 | 1673 | 0.060 |
Why?
|
| Internationality | 1 | 2011 | 1007 | 0.060 |
Why?
|
| Mathematical Computing | 1 | 2005 | 142 | 0.060 |
Why?
|
| Safety | 1 | 2010 | 1157 | 0.060 |
Why?
|
| Depression, Postpartum | 1 | 2010 | 354 | 0.060 |
Why?
|
| Sulfur | 1 | 2005 | 158 | 0.060 |
Why?
|
| Parasympathomimetics | 1 | 1984 | 28 | 0.060 |
Why?
|
| Indoles | 4 | 1997 | 1833 | 0.060 |
Why?
|
| Histamine | 5 | 1975 | 495 | 0.060 |
Why?
|
| Receptors, Adrenergic | 4 | 1988 | 155 | 0.060 |
Why?
|
| Peer Review | 1 | 2007 | 217 | 0.060 |
Why?
|
| Molecular Conformation | 7 | 1994 | 539 | 0.060 |
Why?
|
| Drug Administration Routes | 1 | 2005 | 152 | 0.060 |
Why?
|
| Tyramine | 5 | 1997 | 55 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2013 | 1065 | 0.060 |
Why?
|
| Seasons | 3 | 2007 | 1522 | 0.060 |
Why?
|
| Censuses | 1 | 2006 | 197 | 0.060 |
Why?
|
| Portacaval Shunt, Surgical | 4 | 1980 | 46 | 0.060 |
Why?
|
| Actigraphy | 2 | 2023 | 526 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2010 | 6324 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2018 | 3427 | 0.060 |
Why?
|
| Locomotion | 2 | 1986 | 384 | 0.060 |
Why?
|
| Corticosterone | 2 | 1985 | 301 | 0.060 |
Why?
|
| Manganese | 2 | 1999 | 395 | 0.060 |
Why?
|
| Parvalbumins | 1 | 2006 | 256 | 0.060 |
Why?
|
| Executive Function | 2 | 2010 | 1395 | 0.060 |
Why?
|
| Pulse | 1 | 2004 | 217 | 0.060 |
Why?
|
| Scopolamine | 2 | 1984 | 92 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 14645 | 0.060 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 5 | 1988 | 88 | 0.060 |
Why?
|
| Serotonin Antagonists | 2 | 2002 | 146 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 1994 | 2815 | 0.060 |
Why?
|
| Propylamines | 1 | 2005 | 161 | 0.060 |
Why?
|
| Child, Preschool | 8 | 2017 | 42511 | 0.060 |
Why?
|
| Aminopyridines | 2 | 1999 | 576 | 0.060 |
Why?
|
| Psychoses, Substance-Induced | 4 | 1975 | 98 | 0.060 |
Why?
|
| Legislation, Drug | 1 | 1986 | 216 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2004 | 4133 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 637 | 0.060 |
Why?
|
| Cricetinae | 3 | 2003 | 2413 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 744 | 0.060 |
Why?
|
| Fenclonine | 4 | 1980 | 16 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 2662 | 0.060 |
Why?
|
| Deep Brain Stimulation | 1 | 2012 | 851 | 0.060 |
Why?
|
| Language | 1 | 2013 | 1550 | 0.050 |
Why?
|
| Rehabilitation, Vocational | 1 | 2003 | 70 | 0.050 |
Why?
|
| Bromocriptine | 3 | 1989 | 93 | 0.050 |
Why?
|
| Brain Mapping | 3 | 1997 | 6595 | 0.050 |
Why?
|
| Adoption | 1 | 2004 | 97 | 0.050 |
Why?
|
| Phenoxybenzamine | 3 | 1980 | 53 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3853 | 0.050 |
Why?
|
| Binding Sites | 7 | 1999 | 6001 | 0.050 |
Why?
|
| Schizophrenia, Childhood | 1 | 2003 | 4 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 1001 | 0.050 |
Why?
|
| Morpholines | 1 | 2006 | 584 | 0.050 |
Why?
|
| Protein Binding | 5 | 2008 | 9301 | 0.050 |
Why?
|
| Informed Consent | 3 | 1999 | 1010 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2008 | 576 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2006 | 947 | 0.050 |
Why?
|
| Blood Pressure | 3 | 2006 | 8532 | 0.050 |
Why?
|
| CHO Cells | 2 | 2003 | 1373 | 0.050 |
Why?
|
| History, Medieval | 2 | 2013 | 62 | 0.050 |
Why?
|
| Rats, Inbred SHR | 1 | 2003 | 189 | 0.050 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 686 | 0.050 |
Why?
|
| Conditioning, Operant | 1 | 2004 | 306 | 0.050 |
Why?
|
| Cell Membrane | 8 | 2005 | 3635 | 0.050 |
Why?
|
| Hyperandrogenism | 1 | 2003 | 46 | 0.050 |
Why?
|
| Diet, Reducing | 1 | 2006 | 487 | 0.050 |
Why?
|
| Echocardiography | 1 | 2015 | 5041 | 0.050 |
Why?
|
| Patient Selection | 2 | 2008 | 4249 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2426 | 0.050 |
Why?
|
| Drug Design | 4 | 2015 | 1040 | 0.050 |
Why?
|
| Receptors, Serotonin, 5-HT1 | 1 | 2002 | 14 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 4 | 2003 | 199 | 0.050 |
Why?
|
| Basal Ganglia | 5 | 1980 | 550 | 0.050 |
Why?
|
| Ketanserin | 1 | 2002 | 24 | 0.050 |
Why?
|
| Specialization | 1 | 2007 | 779 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta | 2 | 1981 | 242 | 0.050 |
Why?
|
| Models, Psychological | 2 | 2004 | 823 | 0.050 |
Why?
|
| N,N-Dimethyltryptamine | 2 | 1979 | 4 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 878 | 0.050 |
Why?
|
| Financing, Government | 1 | 2006 | 473 | 0.050 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2012 | 1498 | 0.050 |
Why?
|
| Indians, North American | 1 | 2006 | 354 | 0.050 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 1996 | 582 | 0.050 |
Why?
|
| Sex Characteristics | 2 | 2011 | 2646 | 0.050 |
Why?
|
| Milk, Human | 1 | 2007 | 490 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2002 | 175 | 0.050 |
Why?
|
| Twins | 1 | 2004 | 340 | 0.050 |
Why?
|
| Dosage Forms | 1 | 2002 | 55 | 0.050 |
Why?
|
| Nucleosides | 3 | 1970 | 130 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2004 | 715 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2007 | 934 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 677 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2003 | 337 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2007 | 818 | 0.050 |
Why?
|
| Isomerism | 5 | 1997 | 197 | 0.050 |
Why?
|
| Bioethics | 1 | 2003 | 118 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2008 | 1574 | 0.050 |
Why?
|
| Syndrome | 5 | 2000 | 3270 | 0.050 |
Why?
|
| Biological Transport | 4 | 2004 | 2080 | 0.050 |
Why?
|
| Sodium | 6 | 1989 | 1591 | 0.050 |
Why?
|
| Cerebellar Cortex | 1 | 2002 | 108 | 0.050 |
Why?
|
| Parkinson Disease, Secondary | 2 | 1998 | 120 | 0.050 |
Why?
|
| Infusion Pumps | 1 | 2002 | 163 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 7424 | 0.050 |
Why?
|
| Polysomnography | 1 | 2008 | 1868 | 0.050 |
Why?
|
| Levodopa | 5 | 1984 | 221 | 0.040 |
Why?
|
| Models, Chemical | 3 | 2008 | 607 | 0.040 |
Why?
|
| Amitriptyline | 4 | 1985 | 110 | 0.040 |
Why?
|
| Asia, Western | 1 | 2020 | 19 | 0.040 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 463 | 0.040 |
Why?
|
| Metaraminol | 4 | 1974 | 8 | 0.040 |
Why?
|
| Catechols | 4 | 1973 | 63 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2006 | 838 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2014 | 13046 | 0.040 |
Why?
|
| 1-Naphthylamine | 2 | 1997 | 48 | 0.040 |
Why?
|
| Asia, Southeastern | 1 | 2020 | 115 | 0.040 |
Why?
|
| Subcellular Fractions | 6 | 1988 | 528 | 0.040 |
Why?
|
| Sulfur Radioisotopes | 1 | 2000 | 113 | 0.040 |
Why?
|
| Isoxazoles | 1 | 2002 | 233 | 0.040 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2000 | 87 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2006 | 8924 | 0.040 |
Why?
|
| Carbon Isotopes | 9 | 1973 | 453 | 0.040 |
Why?
|
| Mice | 17 | 2006 | 81839 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2016 | 5089 | 0.040 |
Why?
|
| Methylation | 7 | 1979 | 1074 | 0.040 |
Why?
|
| Receptors, Cholinergic | 1 | 1980 | 243 | 0.040 |
Why?
|
| Muscimol | 1 | 1979 | 70 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 3212 | 0.040 |
Why?
|
| Baclofen | 1 | 2000 | 121 | 0.040 |
Why?
|
| Women's Health | 1 | 2009 | 2081 | 0.040 |
Why?
|
| Water Intoxication | 1 | 1998 | 10 | 0.040 |
Why?
|
| Receptors, Dopamine D5 | 1 | 1998 | 32 | 0.040 |
Why?
|
| Medicine | 1 | 2007 | 944 | 0.040 |
Why?
|
| Physicians | 2 | 2008 | 4591 | 0.040 |
Why?
|
| Guinea Pigs | 7 | 1997 | 1300 | 0.040 |
Why?
|
| Cohort Studies | 6 | 2016 | 41684 | 0.040 |
Why?
|
| Synapses | 5 | 1979 | 1759 | 0.040 |
Why?
|
| Cycloheximide | 1 | 1978 | 339 | 0.040 |
Why?
|
| Paranoid Disorders | 2 | 1992 | 61 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2007 | 1363 | 0.040 |
Why?
|
| Attention | 2 | 2010 | 2415 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 1998 | 143 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2018 | 22228 | 0.040 |
Why?
|
| Counseling | 1 | 2006 | 1553 | 0.040 |
Why?
|
| Potassium | 5 | 1974 | 1312 | 0.040 |
Why?
|
| Hospitals, Teaching | 2 | 2001 | 1156 | 0.040 |
Why?
|
| Pyrroles | 1 | 2004 | 1120 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2006 | 1404 | 0.040 |
Why?
|
| Papio | 3 | 2008 | 671 | 0.040 |
Why?
|
| Ethics | 1 | 1998 | 93 | 0.040 |
Why?
|
| Oxazoles | 1 | 1979 | 198 | 0.040 |
Why?
|
| Textbooks as Topic | 2 | 2011 | 19 | 0.040 |
Why?
|
| Neuroblastoma | 2 | 2005 | 1263 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1983 | 746 | 0.040 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 1998 | 110 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2006 | 2502 | 0.040 |
Why?
|
| Parkinsonian Disorders | 1 | 2000 | 285 | 0.040 |
Why?
|
| Exercise | 2 | 2022 | 5939 | 0.040 |
Why?
|
| Reality Testing | 1 | 2017 | 23 | 0.040 |
Why?
|
| Clinical Medicine | 1 | 1999 | 145 | 0.040 |
Why?
|
| Salicylamides | 2 | 1994 | 31 | 0.040 |
Why?
|
| Receptors, Neurotransmitter | 2 | 1994 | 171 | 0.040 |
Why?
|
| Income | 1 | 2006 | 1874 | 0.030 |
Why?
|
| Fluvoxamine | 1 | 1997 | 77 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 3836 | 0.030 |
Why?
|
| Family | 2 | 2009 | 3208 | 0.030 |
Why?
|
| Temperature | 8 | 1978 | 2227 | 0.030 |
Why?
|
| Depression, Chemical | 5 | 1978 | 186 | 0.030 |
Why?
|
| Infant | 2 | 2017 | 36427 | 0.030 |
Why?
|
| Hydrazines | 3 | 1994 | 223 | 0.030 |
Why?
|
| Reference Values | 4 | 1993 | 4909 | 0.030 |
Why?
|
| Cerebellum | 3 | 1979 | 1519 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 18076 | 0.030 |
Why?
|
| Amino Acids | 4 | 1977 | 1710 | 0.030 |
Why?
|
| Consensus | 2 | 2019 | 3202 | 0.030 |
Why?
|
| Sucrose | 1 | 1977 | 155 | 0.030 |
Why?
|
| Electronic Health Records | 2 | 2014 | 4863 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1986 | 1552 | 0.030 |
Why?
|
| Electrocardiography | 2 | 2004 | 6409 | 0.030 |
Why?
|
| Quality of Life | 2 | 2015 | 13468 | 0.030 |
Why?
|
| Models, Animal | 1 | 2003 | 2120 | 0.030 |
Why?
|
| Hydroxydopamines | 4 | 1990 | 59 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2002 | 3678 | 0.030 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 1996 | 34 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 1985 | 1893 | 0.030 |
Why?
|
| Sulpiride | 1 | 1995 | 13 | 0.030 |
Why?
|
| Electric Stimulation | 6 | 1988 | 1736 | 0.030 |
Why?
|
| Methyldopa | 2 | 1972 | 18 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1977 | 411 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2008 | 273 | 0.030 |
Why?
|
| Hyponatremia | 1 | 1998 | 278 | 0.030 |
Why?
|
| Hospital Bed Capacity | 1 | 1997 | 200 | 0.030 |
Why?
|
| Blepharoptosis | 3 | 1982 | 144 | 0.030 |
Why?
|
| Quinuclidinyl Benzilate | 3 | 1988 | 19 | 0.030 |
Why?
|
| Pyrazines | 1 | 2001 | 1204 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2014 | 6421 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 2689 | 0.030 |
Why?
|
| Cholesterol | 1 | 2004 | 2902 | 0.030 |
Why?
|
| Pyrogallol | 5 | 1975 | 8 | 0.030 |
Why?
|
| Career Mobility | 1 | 1998 | 261 | 0.030 |
Why?
|
| Thermodynamics | 2 | 1987 | 577 | 0.030 |
Why?
|
| Butyrophenones | 4 | 1992 | 15 | 0.030 |
Why?
|
| Calcium | 6 | 1981 | 5770 | 0.030 |
Why?
|
| Myocardium | 9 | 1973 | 4766 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 1997 | 551 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2005 | 12775 | 0.030 |
Why?
|
| Amantadine | 2 | 1972 | 58 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 1993 | 2195 | 0.030 |
Why?
|
| Health Policy | 1 | 2007 | 2700 | 0.030 |
Why?
|
| Neurofibrillary Tangles | 1 | 1997 | 457 | 0.030 |
Why?
|
| Homocystinuria | 1 | 1975 | 66 | 0.030 |
Why?
|
| Memory | 1 | 2004 | 2192 | 0.030 |
Why?
|
| Remission Induction | 1 | 2000 | 2413 | 0.030 |
Why?
|
| Ohio | 1 | 2015 | 320 | 0.030 |
Why?
|
| Movement | 2 | 1978 | 1461 | 0.030 |
Why?
|
| Biochemical Phenomena | 2 | 1965 | 58 | 0.030 |
Why?
|
| Adrenal Cortex | 1 | 2015 | 134 | 0.030 |
Why?
|
| Adrenal Glands | 3 | 1966 | 556 | 0.030 |
Why?
|
| 4-Butyrolactone | 1 | 1994 | 60 | 0.030 |
Why?
|
| Self Disclosure | 1 | 2015 | 249 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2000 | 1181 | 0.030 |
Why?
|
| Carbon Radioisotopes | 4 | 1984 | 543 | 0.030 |
Why?
|
| Biochemistry | 2 | 1965 | 115 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1999 | 785 | 0.030 |
Why?
|
| Autopsy | 1 | 1997 | 1011 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 1998 | 1077 | 0.030 |
Why?
|
| Blood-Brain Barrier | 3 | 2006 | 1036 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2005 | 1331 | 0.030 |
Why?
|
| History, 15th Century | 1 | 2012 | 28 | 0.030 |
Why?
|
| Seasonal Affective Disorder | 1 | 1993 | 49 | 0.030 |
Why?
|
| Crime | 1 | 2014 | 206 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2003 | 3448 | 0.030 |
Why?
|
| Ouabain | 4 | 1974 | 246 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1977 | 1498 | 0.030 |
Why?
|
| London | 1 | 2012 | 233 | 0.030 |
Why?
|
| Leukemia, Myeloid | 2 | 1966 | 695 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 1999 | 1408 | 0.020 |
Why?
|
| Affinity Labels | 1 | 1992 | 107 | 0.020 |
Why?
|
| Phenanthridines | 1 | 1991 | 49 | 0.020 |
Why?
|
| Quinpirole | 1 | 1991 | 27 | 0.020 |
Why?
|
| Phenazocine | 1 | 1991 | 7 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 3 | 2002 | 211 | 0.020 |
Why?
|
| Cyclazocine | 1 | 1991 | 10 | 0.020 |
Why?
|
| Health Education | 1 | 1999 | 1060 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2004 | 14456 | 0.020 |
Why?
|
| Pentazocine | 1 | 1991 | 12 | 0.020 |
Why?
|
| Injections, Intraventricular | 3 | 1988 | 227 | 0.020 |
Why?
|
| Benserazide | 3 | 1976 | 5 | 0.020 |
Why?
|
| Georgia | 1 | 2011 | 186 | 0.020 |
Why?
|
| Impulsive Behavior | 1 | 2014 | 345 | 0.020 |
Why?
|
| Transferases | 3 | 1972 | 71 | 0.020 |
Why?
|
| Diencephalon | 2 | 1986 | 54 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2016 | 803 | 0.020 |
Why?
|
| Pyrimidines | 2 | 2001 | 3050 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1979 | 1794 | 0.020 |
Why?
|
| 2-Chloroadenosine | 1 | 1990 | 11 | 0.020 |
Why?
|
| Biotin | 1 | 1992 | 255 | 0.020 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1990 | 72 | 0.020 |
Why?
|
| Dystonia | 2 | 1988 | 378 | 0.020 |
Why?
|
| Rabbits | 5 | 1984 | 4730 | 0.020 |
Why?
|
| Electrochemistry | 2 | 1988 | 142 | 0.020 |
Why?
|
| Telencephalon | 2 | 1986 | 142 | 0.020 |
Why?
|
| Cost Savings | 1 | 2016 | 901 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 4163 | 0.020 |
Why?
|
| Phenylalanine | 1 | 1972 | 367 | 0.020 |
Why?
|
| Theophylline | 1 | 1990 | 132 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1976 | 2476 | 0.020 |
Why?
|
| Receptors, Purinergic | 1 | 1990 | 66 | 0.020 |
Why?
|
| Catechol O-Methyltransferase | 3 | 1978 | 250 | 0.020 |
Why?
|
| Aorta | 1 | 1978 | 2040 | 0.020 |
Why?
|
| Isoproterenol | 2 | 1981 | 398 | 0.020 |
Why?
|
| Axons | 1 | 1998 | 1677 | 0.020 |
Why?
|
| Synaptic Membranes | 2 | 1982 | 88 | 0.020 |
Why?
|
| Domperidone | 1 | 1989 | 24 | 0.020 |
Why?
|
| Normetanephrine | 4 | 1973 | 25 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 1993 | 992 | 0.020 |
Why?
|
| Gene Expression | 1 | 2002 | 7582 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 1993 | 899 | 0.020 |
Why?
|
| Technetium | 2 | 2000 | 326 | 0.020 |
Why?
|
| Seizures | 2 | 1979 | 2997 | 0.020 |
Why?
|
| Brain Stem | 5 | 1979 | 852 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1981 | 2538 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 937 | 0.020 |
Why?
|
| Pyramidal Tracts | 1 | 1991 | 250 | 0.020 |
Why?
|
| Septal Nuclei | 1 | 1989 | 82 | 0.020 |
Why?
|
| Neural Inhibition | 2 | 1987 | 589 | 0.020 |
Why?
|
| Phenols | 1 | 1973 | 526 | 0.020 |
Why?
|
| 5,6-Dihydroxytryptamine | 2 | 1980 | 5 | 0.020 |
Why?
|
| p-Hydroxyamphetamine | 1 | 1988 | 3 | 0.020 |
Why?
|
| Veratridine | 1 | 1988 | 23 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 1971 | 573 | 0.020 |
Why?
|
| Hydroxylation | 3 | 1973 | 139 | 0.020 |
Why?
|
| Biomedical Research | 2 | 2003 | 3458 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 1971 | 520 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 20137 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2004 | 6545 | 0.020 |
Why?
|
| Activity Cycles | 1 | 1988 | 47 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2018 | 2392 | 0.020 |
Why?
|
| Pyridinium Compounds | 1 | 1988 | 80 | 0.020 |
Why?
|
| Fibroblasts | 3 | 1993 | 4162 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2010 | 459 | 0.020 |
Why?
|
| Antiparkinson Agents | 1 | 1988 | 184 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2003 | 6612 | 0.020 |
Why?
|
| Lung | 4 | 1979 | 10063 | 0.020 |
Why?
|
| Biotransformation | 2 | 2003 | 165 | 0.020 |
Why?
|
| France | 1 | 2009 | 495 | 0.020 |
Why?
|
| Leukocytes | 2 | 1966 | 2030 | 0.020 |
Why?
|
| Kidney | 5 | 1979 | 7072 | 0.020 |
Why?
|
| Probability | 3 | 1993 | 2475 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 1813 | 0.020 |
Why?
|
| Haplorhini | 3 | 1976 | 520 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1995 | 1605 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 11906 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2007 | 189 | 0.020 |
Why?
|
| Hemodynamics | 2 | 1993 | 4188 | 0.020 |
Why?
|
| Pineal Gland | 2 | 1972 | 154 | 0.020 |
Why?
|
| Muridae | 1 | 1986 | 55 | 0.020 |
Why?
|
| Tremor | 2 | 1979 | 197 | 0.020 |
Why?
|
| Radioactive Tracers | 1 | 2006 | 61 | 0.020 |
Why?
|
| Alphaprodine | 1 | 1986 | 2 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2007 | 26381 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2006 | 119 | 0.020 |
Why?
|
| Meperidine | 1 | 1986 | 37 | 0.020 |
Why?
|
| Methysergide | 2 | 1976 | 28 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 4 | 1992 | 410 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 2 | 1993 | 404 | 0.020 |
Why?
|
| Models, Molecular | 2 | 1994 | 5382 | 0.020 |
Why?
|
| Cells, Cultured | 5 | 1994 | 18967 | 0.020 |
Why?
|
| Triglycerides | 1 | 2014 | 2441 | 0.020 |
Why?
|
| Liver Diseases | 2 | 1971 | 1304 | 0.020 |
Why?
|
| Blood Platelets | 4 | 1985 | 2464 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 1988 | 908 | 0.020 |
Why?
|
| Light | 1 | 1992 | 1358 | 0.020 |
Why?
|
| Catatonia | 1 | 2009 | 181 | 0.020 |
Why?
|
| Personality Disorders | 1 | 2010 | 727 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1972 | 1216 | 0.020 |
Why?
|
| Salivary Glands | 1 | 1967 | 231 | 0.020 |
Why?
|
| Transfection | 1 | 1993 | 5739 | 0.020 |
Why?
|
| Skin | 3 | 1978 | 4482 | 0.020 |
Why?
|
| Antimetabolites | 1 | 1965 | 128 | 0.010 |
Why?
|
| Dominance, Cerebral | 2 | 1983 | 616 | 0.010 |
Why?
|
| Pilocarpine | 1 | 1984 | 64 | 0.010 |
Why?
|
| Cats | 3 | 1972 | 972 | 0.010 |
Why?
|
| Membranes | 2 | 1997 | 164 | 0.010 |
Why?
|
| Child Abuse, Sexual | 1 | 2008 | 398 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 1988 | 355 | 0.010 |
Why?
|
| Biopharmaceutics | 1 | 1984 | 22 | 0.010 |
Why?
|
| Proadifen | 3 | 1987 | 11 | 0.010 |
Why?
|
| Creatine | 1 | 2007 | 424 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2007 | 453 | 0.010 |
Why?
|
| Pargyline | 3 | 1976 | 19 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 684 | 0.010 |
Why?
|
| Promethazine | 2 | 1974 | 29 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 3 | 1974 | 289 | 0.010 |
Why?
|
| Osmolar Concentration | 2 | 1977 | 655 | 0.010 |
Why?
|
| Glutamates | 2 | 1976 | 384 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 2395 | 0.010 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2004 | 26 | 0.010 |
Why?
|
| Dinitrophenols | 2 | 1974 | 56 | 0.010 |
Why?
|
| Butaclamol | 1 | 1983 | 5 | 0.010 |
Why?
|
| Neural Pathways | 2 | 1991 | 3079 | 0.010 |
Why?
|
| Phospholipids | 1 | 1987 | 776 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1992 | 1928 | 0.010 |
Why?
|
| Medulla Oblongata | 3 | 1974 | 247 | 0.010 |
Why?
|
| Drug Approval | 1 | 2011 | 820 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 1512 | 0.010 |
Why?
|
| Trichloroacetic Acid | 1 | 1983 | 48 | 0.010 |
Why?
|
| Hypothalamus | 4 | 1973 | 1002 | 0.010 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 1963 | 48 | 0.010 |
Why?
|
| Muscle Contraction | 2 | 1978 | 1207 | 0.010 |
Why?
|
| Phenobarbital | 2 | 1974 | 192 | 0.010 |
Why?
|
| Kidney Diseases | 4 | 1978 | 2100 | 0.010 |
Why?
|
| Methoxyhydroxyphenylglycol | 2 | 1990 | 93 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1993 | 2255 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 2 | 1974 | 297 | 0.010 |
Why?
|
| Thyrotropin | 1 | 2007 | 834 | 0.010 |
Why?
|
| Diazepam | 2 | 1974 | 215 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2005 | 1546 | 0.010 |
Why?
|
| Memory Disorders | 1 | 2010 | 1193 | 0.010 |
Why?
|
| Biological Availability | 2 | 1980 | 387 | 0.010 |
Why?
|
| Patient Readmission | 1 | 1997 | 3283 | 0.010 |
Why?
|
| Leukemia | 2 | 1975 | 1522 | 0.010 |
Why?
|
| Intestines | 1 | 1972 | 1904 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2003 | 5946 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1985 | 1607 | 0.010 |
Why?
|
| Human Experimentation | 1 | 2003 | 124 | 0.010 |
Why?
|
| Cell Count | 1 | 2006 | 1825 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2002 | 42 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 1985 | 550 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2016 | 3798 | 0.010 |
Why?
|
| Vitamin B 12 | 1 | 1965 | 531 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2002 | 69 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 1989 | 838 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1983 | 570 | 0.010 |
Why?
|
| Chemistry, Physical | 1 | 2002 | 152 | 0.010 |
Why?
|
| Trifluoperazine | 1 | 1981 | 40 | 0.010 |
Why?
|
| Clonidine | 1 | 1983 | 170 | 0.010 |
Why?
|
| Spleen | 3 | 1966 | 2294 | 0.010 |
Why?
|
| Psychology | 1 | 2004 | 353 | 0.010 |
Why?
|
| Phenylacetates | 2 | 1972 | 112 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1982 | 274 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1981 | 238 | 0.010 |
Why?
|
| Sleep, REM | 1 | 1985 | 593 | 0.010 |
Why?
|
| p-Chloroamphetamine | 1 | 1980 | 7 | 0.010 |
Why?
|
| Biological Assay | 1 | 1984 | 626 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2004 | 23605 | 0.010 |
Why?
|
| Propranolol | 1 | 1983 | 494 | 0.010 |
Why?
|
| Periodicals as Topic | 1 | 1992 | 1463 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 1885 | 0.010 |
Why?
|
| Hypertension | 2 | 1978 | 8616 | 0.010 |
Why?
|
| Doxepin | 2 | 1983 | 16 | 0.010 |
Why?
|
| Carbonates | 2 | 1970 | 21 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1983 | 956 | 0.010 |
Why?
|
| Raphe Nuclei | 1 | 1980 | 104 | 0.010 |
Why?
|
| Alprenolol | 1 | 1979 | 8 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 1135 | 0.010 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1979 | 99 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1980 | 384 | 0.010 |
Why?
|
| Locus Coeruleus | 1 | 2002 | 241 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 1939 | 0.010 |
Why?
|
| Growth | 1 | 1981 | 365 | 0.010 |
Why?
|
| Urea | 2 | 1972 | 449 | 0.010 |
Why?
|
| Cyproheptadine | 1 | 1979 | 21 | 0.010 |
Why?
|
| Electronics, Medical | 1 | 1979 | 70 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1984 | 1325 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1982 | 657 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 1638 | 0.010 |
Why?
|
| Olfactory Bulb | 2 | 1985 | 198 | 0.010 |
Why?
|
| Chromatography, Paper | 2 | 1974 | 76 | 0.010 |
Why?
|
| Bucladesine | 2 | 1975 | 117 | 0.010 |
Why?
|
| Poisoning | 1 | 1979 | 254 | 0.010 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 1999 | 287 | 0.010 |
Why?
|
| Premedication | 1 | 1978 | 245 | 0.010 |
Why?
|
| Tranylcypromine | 2 | 1988 | 30 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1998 | 284 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1965 | 2602 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 5020 | 0.010 |
Why?
|
| Spinal Cord | 3 | 1974 | 1811 | 0.010 |
Why?
|
| Glycine | 2 | 1974 | 671 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2004 | 1310 | 0.010 |
Why?
|
| Anorexia Nervosa | 1 | 1986 | 1328 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1977 | 244 | 0.010 |
Why?
|
| Phenelzine | 2 | 1988 | 28 | 0.010 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 1976 | 49 | 0.010 |
Why?
|
| Dementia | 2 | 1986 | 2741 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1977 | 643 | 0.010 |
Why?
|
| Mouth | 1 | 1979 | 383 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 1976 | 167 | 0.010 |
Why?
|
| Iproniazid | 2 | 1966 | 8 | 0.010 |
Why?
|
| Neuromuscular Junction | 1 | 1978 | 399 | 0.010 |
Why?
|
| Fluorides | 1 | 1976 | 134 | 0.010 |
Why?
|
| Homocystine | 1 | 1975 | 21 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1997 | 551 | 0.010 |
Why?
|
| Acetylserotonin O-Methyltransferase | 1 | 1975 | 3 | 0.010 |
Why?
|
| Goiter | 1 | 1975 | 86 | 0.010 |
Why?
|
| Tryptophan Hydroxylase | 1 | 1975 | 93 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1977 | 694 | 0.010 |
Why?
|
| Methionine Adenosyltransferase | 1 | 1975 | 16 | 0.010 |
Why?
|
| Methyltyrosines | 1 | 1974 | 7 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1984 | 6215 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1979 | 1751 | 0.010 |
Why?
|
| Electrophoresis, Paper | 1 | 1974 | 14 | 0.010 |
Why?
|
| Mitochondria | 3 | 1974 | 3672 | 0.010 |
Why?
|
| Ammonia | 1 | 1976 | 244 | 0.010 |
Why?
|
| Tetrahydrofolates | 1 | 1975 | 58 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 6102 | 0.010 |
Why?
|
| Father-Child Relations | 1 | 1974 | 48 | 0.010 |
Why?
|
| Fluorometry | 2 | 1972 | 99 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 1979 | 1376 | 0.010 |
Why?
|
| Thiethylperazine | 1 | 1973 | 2 | 0.010 |
Why?
|
| Valinomycin | 1 | 1973 | 17 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1978 | 931 | 0.010 |
Why?
|
| Cesium | 1 | 1973 | 36 | 0.010 |
Why?
|
| Gramicidin | 1 | 1973 | 12 | 0.010 |
Why?
|
| Brain Damage, Chronic | 1 | 1974 | 265 | 0.010 |
Why?
|
| Picrotoxin | 1 | 1973 | 61 | 0.010 |
Why?
|
| Rubidium | 1 | 1973 | 120 | 0.010 |
Why?
|
| Portal System | 1 | 1973 | 49 | 0.010 |
Why?
|
| Ephedrine | 1 | 1973 | 50 | 0.010 |
Why?
|
| Aminolevulinic Acid | 1 | 1974 | 147 | 0.010 |
Why?
|
| Xanthines | 1 | 1973 | 121 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 1974 | 394 | 0.010 |
Why?
|
| Dioxoles | 1 | 1973 | 97 | 0.010 |
Why?
|
| Allosteric Regulation | 1 | 1974 | 425 | 0.010 |
Why?
|
| Cholinesterase Inhibitors | 1 | 1975 | 242 | 0.010 |
Why?
|
| Amphetamines | 1 | 1974 | 142 | 0.010 |
Why?
|
| Erythrocytes | 2 | 1979 | 2394 | 0.010 |
Why?
|
| Rodentia | 1 | 1994 | 263 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 36548 | 0.010 |
Why?
|
| Guanidines | 1 | 1993 | 194 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11035 | 0.010 |
Why?
|
| Magnesium | 1 | 1976 | 815 | 0.010 |
Why?
|
| Sulfides | 1 | 1973 | 168 | 0.010 |
Why?
|
| Mesencephalon | 1 | 1974 | 337 | 0.010 |
Why?
|
| Neurosecretion | 1 | 1972 | 10 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 1998 | 924 | 0.010 |
Why?
|
| Centrifugation | 1 | 1972 | 121 | 0.010 |
Why?
|
| Phenylalanine Hydroxylase | 1 | 1972 | 28 | 0.010 |
Why?
|
| Tetrodotoxin | 1 | 1973 | 244 | 0.010 |
Why?
|
| Reticular Formation | 1 | 1972 | 60 | 0.010 |
Why?
|
| Alkaloids | 1 | 1973 | 191 | 0.010 |
Why?
|
| Deamination | 1 | 1972 | 25 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1972 | 323 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 2844 | 0.010 |
Why?
|
| Amine Oxidase (Copper-Containing) | 1 | 1972 | 41 | 0.010 |
Why?
|
| Gastric Juice | 1 | 1972 | 59 | 0.010 |
Why?
|
| Kanamycin | 1 | 1972 | 63 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 1974 | 575 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1992 | 150 | 0.010 |
Why?
|
| Vanilmandelic Acid | 1 | 1971 | 17 | 0.010 |
Why?
|
| Isoquinolines | 1 | 1973 | 350 | 0.010 |
Why?
|
| Pons | 1 | 1973 | 239 | 0.010 |
Why?
|
| Carboxy-Lyases | 1 | 1972 | 85 | 0.010 |
Why?
|
| Endocrine Glands | 1 | 1972 | 101 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1973 | 396 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1973 | 695 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 1973 | 230 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 3722 | 0.010 |
Why?
|
| Neurochemistry | 1 | 1971 | 29 | 0.010 |
Why?
|
| Dialysis | 1 | 1971 | 72 | 0.010 |
Why?
|
| Life Tables | 1 | 1991 | 366 | 0.010 |
Why?
|
| Glutamine | 1 | 1974 | 575 | 0.010 |
Why?
|
| Estradiol | 1 | 1979 | 1947 | 0.010 |
Why?
|
| Hypotension | 1 | 1997 | 885 | 0.010 |
Why?
|
| Propionates | 1 | 1972 | 180 | 0.010 |
Why?
|
| Histidine | 1 | 1972 | 301 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 1975 | 519 | 0.010 |
Why?
|
| Sterilization | 1 | 1972 | 133 | 0.010 |
Why?
|
| Sexual Behavior, Animal | 1 | 1972 | 120 | 0.010 |
Why?
|
| Choline | 1 | 1973 | 511 | 0.010 |
Why?
|
| Adrenal Medulla | 1 | 1970 | 56 | 0.010 |
Why?
|
| Acetylcholine | 1 | 1973 | 628 | 0.010 |
Why?
|
| Filtration | 1 | 1971 | 227 | 0.010 |
Why?
|
| Mother-Child Relations | 1 | 1974 | 498 | 0.010 |
Why?
|
| Quality Control | 1 | 1993 | 835 | 0.010 |
Why?
|
| Maryland | 1 | 1970 | 278 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 1975 | 705 | 0.010 |
Why?
|
| Benzoates | 1 | 1972 | 213 | 0.010 |
Why?
|
| Synaptic Vesicles | 1 | 1971 | 187 | 0.010 |
Why?
|
| Stomach | 2 | 1972 | 702 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2008 | 4627 | 0.010 |
Why?
|
| Narcolepsy | 1 | 1972 | 200 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1971 | 788 | 0.010 |
Why?
|
| Curriculum | 1 | 2003 | 3784 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1973 | 1138 | 0.000 |
Why?
|
| Prazosin | 1 | 1988 | 95 | 0.000 |
Why?
|
| Gastric Mucosa | 1 | 1972 | 602 | 0.000 |
Why?
|
| Kidney Tubules | 1 | 1970 | 453 | 0.000 |
Why?
|
| Exercise Test | 1 | 1996 | 2185 | 0.000 |
Why?
|
| Heart | 2 | 1972 | 4419 | 0.000 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 1988 | 34 | 0.000 |
Why?
|
| Nervous System | 1 | 1971 | 542 | 0.000 |
Why?
|
| Perphenazine | 1 | 1988 | 33 | 0.000 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 17071 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1971 | 1479 | 0.000 |
Why?
|
| Meningioma | 1 | 1976 | 1221 | 0.000 |
Why?
|
| Child Behavior Disorders | 1 | 1993 | 812 | 0.000 |
Why?
|
| Heart Block | 1 | 1989 | 391 | 0.000 |
Why?
|
| Solvents | 1 | 1988 | 299 | 0.000 |
Why?
|
| Rats, Inbred F344 | 1 | 1988 | 820 | 0.000 |
Why?
|
| Peripheral Nerves | 1 | 1971 | 491 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1977 | 2916 | 0.000 |
Why?
|
| Thiopental | 1 | 1967 | 55 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1997 | 1516 | 0.000 |
Why?
|
| Perfusion | 1 | 1972 | 1408 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1995 | 1172 | 0.000 |
Why?
|
| Skin Diseases | 1 | 1975 | 1083 | 0.000 |
Why?
|
| Aggression | 1 | 1972 | 747 | 0.000 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1966 | 70 | 0.000 |
Why?
|
| Cell Differentiation | 2 | 1981 | 11642 | 0.000 |
Why?
|
| Cycloparaffins | 1 | 1966 | 12 | 0.000 |
Why?
|
| Thalamus | 1 | 1973 | 1040 | 0.000 |
Why?
|
| Histamine Release | 1 | 1966 | 117 | 0.000 |
Why?
|
| Cell Line | 2 | 1997 | 15546 | 0.000 |
Why?
|
| Consciousness | 1 | 1972 | 601 | 0.000 |
Why?
|
| Pentobarbital | 1 | 1966 | 153 | 0.000 |
Why?
|
| Methods | 2 | 1979 | 1061 | 0.000 |
Why?
|
| Isocarboxazid | 1 | 1965 | 7 | 0.000 |
Why?
|
| Polymers | 1 | 1973 | 1622 | 0.000 |
Why?
|
| Terminology as Topic | 1 | 1993 | 1536 | 0.000 |
Why?
|
| Hyperphagia | 1 | 1986 | 139 | 0.000 |
Why?
|
| Anemia | 1 | 1995 | 1514 | 0.000 |
Why?
|
| Droperidol | 1 | 1985 | 21 | 0.000 |
Why?
|
| Ketones | 1 | 1966 | 183 | 0.000 |
Why?
|
| Random Allocation | 1 | 1989 | 2395 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 1976 | 2894 | 0.000 |
Why?
|
| Toxicology | 1 | 1965 | 102 | 0.000 |
Why?
|
| Stress, Physiological | 1 | 1972 | 1405 | 0.000 |
Why?
|
| Species Specificity | 1 | 1988 | 2406 | 0.000 |
Why?
|
| Sexual Maturation | 1 | 1986 | 256 | 0.000 |
Why?
|
| Niacinamide | 1 | 1966 | 419 | 0.000 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1985 | 618 | 0.000 |
Why?
|
| Exploratory Behavior | 1 | 1984 | 271 | 0.000 |
Why?
|
| Circular Dichroism | 1 | 1983 | 333 | 0.000 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1982 | 143 | 0.000 |
Why?
|
| Learning | 1 | 1972 | 1755 | 0.000 |
Why?
|
| Models, Biological | 1 | 1979 | 9445 | 0.000 |
Why?
|
| Dogs | 1 | 1966 | 3824 | 0.000 |
Why?
|
| Glioma | 1 | 1976 | 3491 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1985 | 20700 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1983 | 825 | 0.000 |
Why?
|
| Radiometry | 1 | 1966 | 804 | 0.000 |
Why?
|
| Heart Atria | 1 | 1967 | 1363 | 0.000 |
Why?
|
| Posture | 1 | 1985 | 955 | 0.000 |
Why?
|
| Peptides | 1 | 1973 | 4338 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1981 | 515 | 0.000 |
Why?
|
| Aluminum Oxide | 1 | 1979 | 40 | 0.000 |
Why?
|
| Feeding Behavior | 1 | 1972 | 3209 | 0.000 |
Why?
|
| Adsorption | 1 | 1979 | 198 | 0.000 |
Why?
|
| Glucose | 1 | 1970 | 4335 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1981 | 2543 | 0.000 |
Why?
|
| Sleep | 1 | 1972 | 4816 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1976 | 9065 | 0.000 |
Why?
|
| Nialamide | 1 | 1974 | 5 | 0.000 |
Why?
|
| Astrocytoma | 1 | 1976 | 772 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1997 | 15647 | 0.000 |
Why?
|
| Cerebral Hemorrhage | 1 | 1982 | 2649 | 0.000 |
Why?
|
| Enzyme Activation | 1 | 1975 | 3584 | 0.000 |
Why?
|
| Melatonin | 1 | 1972 | 670 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1972 | 2003 | 0.000 |
Why?
|
| Uterus | 1 | 1966 | 660 | 0.000 |
Why?
|